References

The Natural Pcos Diet

Most Effective Polycystic Ovarian Syndrome Treatments

Get Instant Access

1. Barker DJP, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;345:938-941

2. Barker DJP, Hales CN, Fall CH, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome x): relation to reduced fetal growth. Diabetologia 1993;36:62-67

3. Ibanez L, Potau N, Francois I, De Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-3562

4. Gluckman PD, Hanson MA. The developmental origins of the metabolic syndrome. Trends Endocrinol Metab 2004;15:183-187

5. Lucas A. Programming by early nutrition in man. Ciba Found Symp 1991;156:38-50

6. Fowden AL, Giussani DA, Forhead AJ. Intrauterine programming of physiological systems: causes and consequences. Physiology 2005;21:29-37

7. Seckl JR. Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol 2000;185:61-71

8. Arai Y, Gorski RA. Critical exposure time for androgenization of the developing hypothalamus in the female rat. Endocrinology 1968;82:1010-1014

9. Gustafsson J-A, Mode A, Norstedt G, Skett P. Sex steroid induced changes in hepatic enzymes. Annu Rev Physiol 1983;45:51-60

10. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002;174:1-5

11. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749

12. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236

13. Ehrmann DA, Liljenquist DR, Kasra K et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53

14. Kravariti M, Naka KK, Kalantaridou SN et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088-5095

15. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861

16. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25

17. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a national approach. In: Dunaif A, Givens JR, Haseltine FP (eds). Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Boston, MA: Blackwell, 1992, pp. 337-384

18. Azziz R, Carmina E, Dewailly B, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.

19. Nelson VL, Legro RS, Strauss JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946-957

20. Wickenheisser JK, Nelson-De Grave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol Metab 2006;17:63-69

21. Wood JR, Nelson VL, Ho C, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003;278:26380-26390

22. Wood JR, Ho CK, Nelson-De Grave VL, McAllister JM, Strauss JF III. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol 2004;63:51-60

23. Jansen E, Laven JSE, Dommerhot HBR, et al. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol 2004;18:3050-3063

24. Xita N, Tsatsoulis A. Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006;91:1660-1666

25. Haque WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf) 1990;33:501-510

26. Barnes RB, Rosenfield RC, Ehrmann DA et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994;79:1328-1333

27. Miller WL. P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 2004;15:311-315

28. Morishima A, Grumbach MM, Simpson ER, Fisher C, Kenan Q. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698

29. Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL. Human sex-hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Invest 2002;109:973-981

30. Abbott DH, Dumesic DA, Eisner JR, Kemnitz JW, Goy RW. The prenatally androgenized female rhesus monkey as a model for polycystic ovarian syndrome. In: Azziz R, Nestler JE, Dewailly D (eds). Androgen Excess Disorders in Women. Philadelphia, PA: Lippincott-Raven, 1997, pp. 369-382

31. Resko JA, Buhl AE, Phoenix CH. Treatment of pregnant rhesus macaques with testosterone propionate: observations on its fate in the fetus. Biol Reprod 1987;37:1185-1191

32. Eisner JR, Barnett MA, Dumesic DA, Abbott DH. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril 2002;77:167-172

33. Zhou R, Bird IM, Dumesic DA, Abbott DH. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:6630-6637

34. Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW. Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab 1998;9:62-67

35. Padmanabhan V, Evans N, Taylor JA, Robinson JE. Prenatal exposure to androgens leads to the development of cystic ovaries in the sheep. Biol Reprod 1998;56(Suppl 1):194

36. Dumesic DA, Abbott DH, Eisner JR, Goy RW. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril 1997;67:155-163

37. Robinson JE, Forsdike RA, Taylor JA. In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology 1999;140:5797-5805

38. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome. Hum Reprod Update 2005;11:357-374

39. Eisnher JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes Res 2003;11:279-286

40. Bruns CM, Baum ST, Colman RJ, et al. Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome (PCOS). Int J Obes 2007;31:1579-1585

41. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 2000;85:1206-1210

42. Recabarren SE, Padmanabhan V, Codner E, et al. Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol 2005;289:E801-E806

43. King AJ, Olivier NB, Mohankumar PS, Lee JS, Padmanabham V, Fink GD. Hypertension caused by prenatal testosterone excess in female sheep. Am J Physiol Endocrinol Metab, 2007;292:E1837-E1841

44. Bruns CM, Baum ST, Colman RJ, et al. Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J Clin Endocrinol Metab 2004;89:6218-6223

45. Ibanez L, Dimartino-Nardi J, Potan N, Saenger P. Premature adrenarche-normal variant or forerunner of adult disease? Endocr Rev 2000;21:671-696

46. Ibanez L, Potau N, deZegher FI. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-3562

47. Charkaluk ML, Trivin C, Brauner R. Premature pubarche as an indicator of how body weight influences the onset of adrenarche. Eur J Pediatr 2004;163:89-93

48. Meas T, Chevenne D, Thibaud E, et al. Endocrine consequences of premature pubarche in postpubertal caucasian girls. Clin Endocrinol (Oxf) 2002;57:101-106

49. Ibanez L, Potau N, Marcos MV, de Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab 1999;84:4739-4741

50. Ghirri P, Bernardini M, Vuerich M, et al. Adrenarche, pubertal development, age at menarche and final height of full-term, born small for gestational age (SGA) girls. Gynecol Endocrinol 2001;15:91-97

51. Veening MA, van Weissenbruch MM, Roord JJ, de Delamarre-van Waal HA. Pubertal development in children born small for gestational age. J Pediatr Endocrinol Metab 2004;17:1497-1506

52. Ong KK, Potau N, Petry CJ, et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004;89:2647-2651

53. De Zegher F, Ibanez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to poly-cystic ovary syndrome. Fertil Steril 2006;86:S4-S5

54. Ibanez L, Jaramillo A, Enriquez G, et al. Polycystic ovaries after precocious pubarche: relation to prenatal growth. Hum Reprod 2007;22:395-400

55. Barker DJ, Eriksson TG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int Epidemiol 2002;31:1235-1239

56. Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997;350:1131-1135

57. Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710-715

58. Michelmore K, Ong K, Mason S, et al. Clinical features of women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001;55:439-446

59. Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental llb-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997;46:161-166

60. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002;17:2573-2579

61. Sir-Petermann T, Devoto L, Maliqueo M, Peirano P, Recabarren SE, Wildt L. Resumption of ovarian function during lactational amenorrhoea in breastfeeding women with polycystic ovarian syndrome: endocrine aspects. Hum Reprod 2001;16:1603-1610

62. Mason JI, Vshijima K, Doody KM, et al. Regulation of expression of the 3b-hydroxysteroid dehydrogenase of human placenta and fetal adrenal. J Steroid Biochem Mol Biol 1993;47:151-159

63. Nestler JE. Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor-1. Endocrinology 1987;121:1845-1852

64. Nestler JE. Insulin and insulin-like growth factor-1 stimulate the 3b-hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts. Endocrinology 1989;125:2127-2133

65. Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-89

66. Sam S, Legro RS, Essah P, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006;103:7030-7035

67. Sir-Petermann T, Maliqueo M, Codner E et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:4637-4642

68. Sir-Petermann T, Codner E, Maliqueo M, et al. Increased anti-mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:3105-3109

69. Sir-Petermann T, Hitchsfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005;20:2122-2126

70. Turhan NO, Seckin NC, Rybar F, Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynecol Obstet 2003;81:163-168

71. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323-1330

72. Gartsen SM, Jacobsen G, Romundstad P. Maternal testosterone levels during pregnancy are associated with offspring size at birth. Eur J Endocrinol 2006;155:365-370

73. Steckler T, Wang T, Bartol FF, Roy SK, Padmanabhan V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 2005;146:3185-3193

74. Gitau R, Adams D, Fisk NM, Glover V. Fetal plasma testosterone correlates positively with cortisol. Arch Dis Child Fetal Neonatal Ed 2005;90:F166-F169

75. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997;277:1669-1672

76. Zhou Y, Genbacer O, Damsky CH, Fisher SJ. Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and pre-eclampsia. J Reprod Immunol 1998;39: 197-213

77. Zamudio S, Leslie KK, White M, Hagerman DD, Moore LG. Low serum estradiol and high serum progesterone concentrations characterize hypertensive pregnancies at high altitude. J Soc Gynecol Investig 1994;1:197-205

78. Jiang B, Kamat A, Mendelson CR. Hypoxia prevents induction of aromatase expression in human trophoblast cells in culture: potential inhibitory role of the hypoxia-inducible transcription factor Mash-2 (Mannalien Achaete-Scute Homologous Protein2). Mol Endocrinol 2000;14:1661-1673

79. Tchernof A, Toth MJ, Poehlanan ET. Sex hormone-binding globulin levels in middle-aged premenopausal women. Association with visceral obesity and metabolic profile. Diabetes Care 1999;22:1875-1881

80. Haffner SM, Katz MS, Stern MP, Dunn JF. The relationship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 1988;67:460-464

81. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1998;67:460-464

82. Selvo DM, Hogerveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 2007;117:3979-3987

83. Dickenson SM, Gore AC. Estrogenic environmental endocrine-disrupting chemical effects on reproductive neuroendocrine function and dysfunction across the life cycle. Rev Endocr Metab Disord 2007;8:143-159

84. Gupta C. Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Proc Soc Exp Biol Med 2000;224:61-68

85. Haney AF, Newbold RR, McLachlan JA. Prenatal diethylstilbestrol exposure in the mouse: effects on ovarian histology and steroidogenesis in vitro. Biol Reprod 1984;30:471-478

86. Wu CH, Mangan CE, Burtnett MM, Michail G. Plasma hormones in DES-exposed females. Obstet Gynecol 1980;55: 157-162

87. Bibbo M, Gill WB, Azizi F, et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol 1977;49:1-8

88. Newbold RR, Padilla-Banks E, Snydrer RJ, Jefferson WN. Perinatal exposure to environmental estrogens and the development of obesity. Mol Nutr Food Res 2007;51:912-917

89. Matthiessen P, Gibbs P. Critical appraisal of the evidence for tributyltin-mediated endocrine disruption in mollusks. Environ Toxicol Chem 1998;17:37-43

90. Ogata R, Omara M, Shimasaki Y, et al. Two-generation reproductive toxicity study of tributyltin chloride in female rats. J Toxicol Environ Health 2001;63:127-144

91. Cooke GM. Effect of organotins on human aromatase activity in vitro. Toxicol Lett 2002;126:121-130

92. Mu YM, Yanase T, Nishi Y, Takayanagi R, Goto K, Nawata H. Combined treatment with specific ligands for PPARg: RXR nuclear receptor system markedly inhibits the expression of cytochrome P450 arom in human granulosa cancer cells. Mol Cell Endocrinol 2001;181:239-248

93. Grun F, Watanabe H, Zamanian Z, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol 2006;20:2141-2155

94. Grun F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signalling. Endocrinology 2006;147:550-555

95. Berube D, Sevalini GE, Gagne R, Hammond GL. Localization of human sex hormone-binding gene (SHBG) to the short arm of chromosome 17(17p12-p13). Cytogenet Cell Genet 1990;54:65-67

96. Toscano V, Balducci R, Bianchi P, Guglielmi R, Mangiantini A, Sciara F. Steroidal and non-steroidal factors in plasma sex hormone binding globulin regulation. J Steroid Biochem Mol Biol 1992;43:431-437

97. Ahrentsen OD, Jensen HK, Johnsen SG. Sex hormone-binding globulin deficiency 1982;2:377-378

98. Hogeveen KN, Talikka M, Hammond GL. Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem 2001;276:36383-36390

99. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG)gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003;88:5976-5980

100. Cousin P, Calemard-Michel L, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D 327 N polymorphism on serum sex hormone-binding globulin concentrations in hirsuit women. J Clin Endocrinol Metab 2004;89:917-924

101. Polonca F, Teran N, Gersak K. The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod 2007;22:1031-1036

102. Bulun SE. Aromatase deficiency in women and men: would you have predicted the phenotype? J Clin Endocrinol Metab 1996;81:867-871

103. Urbanek M, Legro RS, Driscoll DA et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999;69:8573-8578

104. Soderlund D, Canto P, Carranza-Lira S, Méndez JP. No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Hum Reprod 2005;20:965-969

105. Gharani N, Waterworth BW, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402

106. Petry CJ, Ong KK, Michelmore KF, et al. Association of aromatase (CYP19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837-1843

107. Baghaei F, Rosmond R, Westberg L, et al. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res 2003;11:578-585

108. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype. Eur J Endocrinol 2008;158:861-865

109. Gaasenbeek M, Powell BL, Sovio U et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 2004;89:2403-2413

110. Kimura S, Matsumoto T, Matsuyama K et al. Androgen receptor function in folliculogenesis and its clinical implication in premature ovarian failure. Trends Endocrinol Metab 2007;18:181-189

111. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-3186

112. Westberg L, Baghaei F, Rosmond R, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor ß gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001;86:2562-2568

113. Ibanez L, Ong KK, Mongan N, et al. Androgen receptor gene CAG repeat polymorphism in development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003;88:3333-3338

114. Legro RS, Shahbahrami B, Lobo PA, Kovacs BW. Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994;83:701-706

115. Misfud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000;85:3484-3488

116. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-165

117. Calvo RM, Asuncion M, Saucho J, San Millan JL, Escobar-Morreale HF. The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation in the pathogenesis of hirsutism. J Clin Endocrinol Metab 2000;85:1735-1740

118. Jaaskelainen J, Korhonen S, Voutilainen R, Hippelainen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil Steril 2005;83:1724-1728

119. Edwarls A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variations at five trimenic and tetramenic tandem repeat loci in four human population groups. Genomics 1992; 241-253

120. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The role of sex hormone-binding globulin and androgen reception gene variants in the development of polycystic ovary syndrome. Hum Reprod 2008;23:693-698

121. Britt KL, Findlay JK. Estrogen actions in the ovary revisited. J Endocrinol 2002; 175:269-276

122. Robinson J. Prenatal programming at the female reproductive neuroendocrine system by androgens. Reproduction 2006; 132:539-547

123. Escobar-Morreale HF, Sam Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266-272

124. Auger AP, Hexter DP, McCarthy MM. Sex differences in the phosphorylations of cAMP response element binding protein (CREB) in neonatal fat brain. Brain Res 2001; 890:110-117

125. Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic disease. Nutrition 2004; 20:63-68

126. Li Z, Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses 2008; 70:638-642

127. Lavoie HA. Epigenetic control of ovarian function: the emerging role of histone modification. Mol Cell Endocrinol 2005; 243:12-18

128. Drake AJ, Walker BR. The intergenerational effects of fetal programming: non-genomic mechanisms for the inheritance of low birth weight and cardiovascular risk. J Endocrinol 2004; 180:1-16

129. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26:251-282

Was this article helpful?

0 0
Weight Loss All Star

Weight Loss All Star

Are you looking to lose weight or even just tone up? What is stopping you from having the body you want and help you feel great at the same time? I created Weight Loss All-Star for all those wanting to lose weight, and keep the weight off. I know how hard it is to do diets and stick with them, and get the motivation to get up and exercise.

Get My Free Ebook


Post a comment